1. Flow of Patients Through Trial
Nissen SE, et al. JAMA 2008;299:

2. Baseline Characteristics of the Study Population (n=839)a
Nissen SE, et al. JAMA 2008;299:

3. Body Weight, Waist Circumference, Metabolic Outcomes, and Blood Pressure in Patients Completing the Trial (n=676)a
Nissen SE, et al. JAMA 2008;299:

4. Effects of Rimonabant on Body Weight, Waist Circumference, and Levels of HDL-C, Triglycerides, Fasting Insulin, and Glycated Hemoglobin (HbA1c)
Nissen SE, et al. JAMA 2008;299:

5. Baseline, Follow-up, and Change from Baseline in Intravascular Ultrasound End Points in Patients Completing the Trial (n = 676)
Nissen SE, et al. JAMA 2008;299:

6. Primary Efficacy Parameter (Percent Atheroma Volume) in Subgroups
Nissen SE, et al. JAMA 2008;299:

7. Major Cardiovascular Adverse Events, Treatment-Emergent Adverse Events, and Reasons for Study Drug Discontinuation (Randomized Population, n=839)
Nissen SE, et al. JAMA 2008;299:

8. Cumulative Incidence of Drug Discontinuation
Nissen SE, et al. JAMA 2008;299: